Clinical trial · Observational
Superselective Intra-arterial Chemotherapy Treatment for Retinoblastoma- 5 Year Results From Turkey
NCT03935074CI-TRIAL-00038476completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Retrospective review of 5-year long term outcomes of superselective intra-arterial chemotherapy treatment in retinoblastoma in a single institute. The treatment outcomes, globe salvage rates and complications of superselective intra-arterial chemotherapy both for treating naive patients (primary treatment group) and for patients who received systemic chemotherapy previously (secondary treatment group) were evaluated.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Retinoblastoma | Retinoblastoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| intra-arterial administration of melphalan | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- group 1
- description
- Patients who received intra-arterial chemotherapy as a first line treatment
- interventionNames
- Drug: intra-arterial administration of melphalan
- label
- group 2
- description
- Patients who received intra-arterial chemotherapy as a salvage treatment after systemic chemotherapy
- interventionNames
- Drug: intra-arterial administration of melphalan
Primary outcomes (1)
- measure
- globe salvage
- timeFrame
- 2-5 years
- description
- globe salvage rate after superselective intra-arterial chemotherapy treatment for retinoblastoma
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 5 Months
- Maximum age
- 7 Years
Show eligibility criteria text
Inclusion Criteria: * patients diagnosed with unilateral/bilateral retinoblastoma Exclusion Criteria: * patients with trilateral retinoblastoma * extraoculer involvement * patients with blood dyscrasias, bleeding and clotting disorders
References
Publications (1)
- BACKGROUNDSaglam M, Sarici A, Anagnostakou V, Yildiz B, Kocer N, Islak C, Kizilkilic O. An alternative technique of the superselective catheterization of the ophthalmic artery for intra-arterial chemotherapy of the retinoblastoma: retrograde approach through the posterior communicating artery to the ophthalmic artery. Neuroradiology. 2014 Sep;56(9):751-4. doi: 10.1007/s00234-014-1388-1. Epub 2014 Jun 10. PMID 24913287